Target intelligence / Profile preview

Cas12a off-target genomic DNA sites (Cas12a off-targets)

Target
Cas12a off-targets
Molecular classification
Genomic DNA, Nucleic acid
01

Overview

Cas12a off-target genomic DNA sites are unintended loci within the genome where the Cas12a (formerly Cpf1) endonuclease binds and cleaves due to sequence similarity with the intended target. These sites typically possess a compatible Protospacer Adjacent Motif (PAM), such as TTTN, and exhibit partial complementarity to the CRISPR RNA (crRNA) guide sequence (Zetsche et al., 2015, Cell). While Cas12a is generally noted for higher specificity compared to Cas9, off-target activity remains a significant concern in gene editing applications as it can lead to double-strand breaks at non-target locations (Kim et al., 2016, Nature Biotechnology). Such unintended modifications can result in genomic instability, gene disruptions, or chromosomal translocations, potentially leading to cellular dysfunction or oncogenic transformation (Kleinstiver et al., 2016, Nature Biotechnology). The kinetics of Cas12a binding suggest that mismatches in the seed region of the crRNA are less tolerated than those in the distal region, though off-target cleavage can still occur at sites with multiple mismatches (Strohkendl et al., 2018, Molecular Cell). Monitoring and minimizing these off-target effects is a critical component of safety assessments for CRISPR-Cas12a-based therapeutics. Identifying these sites often requires specialized empirical methods like GUIDE-seq or CIRCLE-seq to ensure the safety and precision of the genetic intervention.

Other names
Cpf1 off-target sitesCas12a off-targetsUnintended genomic cleavage sitesNon-specific Cas12a binding sites
02

Mechanism of action

Unintended endonucleolytic cleavage of double-stranded DNA at genomic loci with partial complementarity to the guide RNA.

03

Biological functions

DNA cleavageMutagenesisGenomic instability
04

Disease associations

CancerGenetic disorder
05

Safety considerations

GenotoxicityChromosomal translocationsOncogene activationTumor suppressor inactivation
06

Interacting drugs

CRISPR-Cas12a gene editing systems

2 more in the full profile.

07

Biomarkers

GUIDE-seqCIRCLE-seqDigenome-seqSITE-Seq

Beyond the preview

Go deeper on Cas12a off-target genomic DNA sites (Cas12a off-targets).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cas12a off-target genomic DNA sites (Cas12a off-targets).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call